• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Uncle Bud's Health & Wellness Experiencing Powerful Growth One Month Following Acquisition by Pressure BioSciences, Inc.

    2/26/24 9:06:01 AM ET
    $PBIO
    Get the next $PBIO alert in real time by email

    SOUTH EASTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biotherapeutics, and more, is excited to announce promising early financial results from its January 19, 2024 acquisition of Uncle Bud's Health & Wellness ("UB").

    Key highlights from Uncle Bud's first month following its acquisition by PBIO include:

    • Amazon Business Rapid Growth: Amazon sales have surged, increasing 60% over the previous month. This acceleration leverages underlying growth in consumer demand for Uncle Bud's trusted natural wellness products.
    • Direct-to-Consumer (DTC) Sales Increase: DTC sales experienced a 16% increase from the previous month, reflecting the solidifying base of loyal customers and a growing interest in the brand's unique offerings.
    • Expansion of DTC Customer Base: New DTC customers have grown by 13% compared to the previous month, reflecting the brand's expanding appeal and its successful outreach efforts.
    • Unprecedented DTC Subscription Growth: New DTC subscriptions have surged by a robust 138% since the previous month, showcasing consumers' growing trust and preference for UB's products.
    • Website Traffic Increase: Unique visitors to UB's website have increased by 142%, signaling a significant rise in brand awareness and interest in the brand's holistic wellness solutions.
    • Celebrity Endorsements on the Horizon: UB is in discussions with several high-profile celebrities to join UB, with compelling personal endorsements to further elevate the brand's visibility and appeal.
    • Influencer Campaign Launch: UB is set to launch an extensive influencer campaign, partnering with one of the largest influencer platforms to engage both micro and macro influencers. This initiative is expected to broaden the brand's reach and deepen its connection with consumers.
    • Premium Collection Introduction: UB recently announced the introduction of a new Premium Collection of products, all of which will be processed with PBIO's revolutionary, patented UltraShear™ nanoemulsification platform, resulting in measurably increased speed of action, dosing payload delivery, bioavailability, and stability.

    "We are thrilled to witness such dynamic growth in our DTC metrics, a testament to the trust and loyalty our customers have in Uncle Bud's products, as well as anticipatory excitement for the promise of PBIO's new nanoemulsion product enhancement capabilities. The significant upswing in new subscriptions, customers, revenue, and website traffic are not just numbers to us; they represent real people exploring and definitively choosing better-for-you wellness and natural solutions for their everyday lives," said Garrett Greller, Director of Marketing at Uncle Bud's.

    Mr. Greller continued: "Moreover, our forthcoming collaborations with high-profile celebrities and the launch of our influencer campaign will not only enhance brand visibility but will reinforce our deep-rooted engagement and adoption of cutting-edge science-driven improvements. They will also strengthen our mission to make Uncle Bud's extraordinary wellness accessible to everyone. We are on an exciting path of growth and innovation, and these results are just the beginning of what promises to be a rewarding journey ahead for all PBIO stakeholders."

    About Uncle Bud's

    Launched in 2018 with a trailblazing hemp-based Pain Relief product, Uncle Bud's has rapidly captured an innovative leadership role in the Hemp Seed Oil, Cannabidiol (CBD), and the broader Health & Wellness industry. The Uncle Bud's brand is revered for its unwavering commitment to domestic manufacturing excellence, setting benchmarks for its organic, preservative-free, non-GMO standards and its ethical cruelty-free practices. Uncle Bud's is dedicated to the highest-quality formulations and to continuous improvement, guided by the latest scientific research and development innovations – including the revolutionary performance breakthroughs delivered by PBIO's patented UltraShear™ processing platform. Uncle Bud's diverse product portfolio addresses an ever-broadening spectrum of consumer needs, encompassing pain relief, sophisticated skincare solutions, personal wellness and athletic recovery products, and specialized pet care items. Learn More: www.unclebudshemp.com * Follow On Social Media: @UncleBuds_Hemp.

    Pressure BioSciences, Inc.

    Pressure BioSciences, Inc. (OTCQB:PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our patented enabling platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. Our patented BaroFold™ technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.

    Forward Looking Statements

    This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

    For more information about PBIO, Uncle Bud's, and this press release, please click on the following website links:

    http://www.pressurebiosciences.com    www.unclebudshemp.com

    Please visit us on Facebook, LinkedIn, and Twitter.



    Press Co
    ntacts:
     
    Richard T. Schumacher, President & CEO (508) 230-1828 (T)
    John B Hollister, Director of Sales and Marketing(805) 908-5719 (T)
    Bruno Schiavi, President, Uncle Bud's Health & Wellness (508) 230-1828 (T)


    Primary Logo

    Get the next $PBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBIO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ET

      CANTON, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics. The teleconference is scheduled for Thursday, June 20, 2024 at 4:30pm ET. Topics to be discussed include: FY 2023 financial and business results.FY 2024 financial and business outlook.Status of Company's relocation to its new manufacturing facility.Status of Company's new Joint Venture Program.Update on Uncle Bud's Health and WellnessProduct expansion – expected Q3/Q4 2024 release of new nanoemulsified products, i

      6/18/24 8:16:05 AM ET
      $PBIO
    • Pressure BioSciences, Inc. to Host Business and Financial Update on Wednesday, June 19th at 4:30pm ET

      SOUTH EASTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics. The teleconference is scheduled for Wednesday, June 19, 2024 at 4:30 PM ET. The topics to be discussed include but are not limited to: FY 2023 financial and business results.FY 2024 financial and business outlook.Status of Company's relocation to its new manufacturing facility.Update on Uncle Bud's Health and WellnessProduct expansion – expected Q3/Q4 2024 commercial release of new nanoemulsified products: N

      6/13/24 10:13:34 AM ET
      $PBIO
    • Uncle Bud's Health and Wellness to Expand New Premium Collection with Novel Products for Sleep, Memory, Pain, Immunity, Feminine Hygiene, and Sexual Wellness

      SOUTH EASTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for the health & wellness, food & beverage, nutraceutical, cosmeceutical, and other industries, today revealed that its wholly-owned Uncle Bud's Health & Wellness direct-to-consumer ("DTC") subsidiary ("Uncle Bud's") has announced an expansion of products and categories in 2024 to its recently formed "Premium Collection" of state-of-the-art nanoemulsified products. Premium Collection products

      4/11/24 10:52:23 AM ET
      $PBIO

    $PBIO
    Financials

    Live finance-specific insights

    See more
    • Uncle Bud's to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences UltraShear Processing for Revolutionary Product Effectiveness

      Multi-Patented Nanoemulsification Platform Enables Wide-Range of Best-in-Class Health and Wellness Products - Revenue Impact of $5 Million in 2024 Anticipated with Further Acceleration in 2025 & Beyond Pressure BioSciences February 5th Investor Call to Discuss Impact of Recent Uncle Bud's Acquisition SOUTH EASTON, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biothe

      2/5/24 8:23:04 AM ET
      $PBIO
    • Pressure BioSciences, Inc. Reports Q3 2023 Financial Results, Provides Business Update, and Offers Guidance for Remainder of 2023

      Investor Call Scheduled for Tuesday, November 21, 2023 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / November 21, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmeceuticals, agriculture, and food & beverage industries, today reported financial results for the third quarter ended September 30, 2023, provided a business update, and offered limited guidance for expected achievements through the remainder of 2023.Financial Highlights: Q3 2023 vs. Q3 2022 (rounded to nearest

      11/21/23 9:28:00 AM ET
      $PBIO
    • Pressure BioSciences, Inc. to Discuss Third Quarter 2023 Financial Results and Provide Business Update

      Conference Call Scheduled for Tuesday, November 21 at 4:30pm ETSOUTH EASTON, MA / ACCESSWIRE / November 20, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to discuss its Third Quarter 2023 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website) approximately one day after the teleconference.The teleconference will include a Company presentation followed by a Question & Answer period.Date: Tuesday, November 21, 2023. Time: 4:30 PM Eastern Time (ET).To attend thi

      11/20/23 9:15:00 AM ET
      $PBIO

    $PBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Uncle Bud's Health & Wellness Experiencing Powerful Growth One Month Following Acquisition by Pressure BioSciences, Inc.

      SOUTH EASTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biotherapeutics, and more, is excited to announce promising early financial results from its January 19, 2024 acquisition of Uncle Bud's Health & Wellness ("UB"). Key highlights from Uncle Bud's first month following its acquisition by PBIO include: Amazon Business Rapid Growth: Amazon sales have surged, inc

      2/26/24 9:06:01 AM ET
      $PBIO

    $PBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Peterson Jeffrey N acquired $1,670 worth of shares (59,652 units at $0.03), increasing direct ownership by 72% to 142,084 units (SEC Form 4)

      4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)

      9/30/24 4:05:23 PM ET
      $PBIO
    • Director Urdea Michael S acquired $404 worth of shares (14,429 units at $0.03), increasing direct ownership by 44% to 47,588 units (SEC Form 4)

      4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)

      9/30/24 4:05:20 PM ET
      $PBIO
    • President, CEO Schumacher Richard T acquired $641 worth of shares (22,878 units at $0.03), increasing direct ownership by 38% to 82,967 units (SEC Form 4)

      4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)

      9/30/24 4:05:21 PM ET
      $PBIO

    $PBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pressure BioSciences, Inc. (Amendment)

      SC 13G/A - PRESSURE BIOSCIENCES INC (0000830656) (Subject)

      7/30/21 2:54:00 PM ET
      $PBIO
    • SEC Form SC 13G filed by Pressure BioSciences, Inc.

      SC 13G - PRESSURE BIOSCIENCES INC (0000830656) (Subject)

      7/16/21 2:44:13 PM ET
      $PBIO

    $PBIO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pressure BioSciences, Inc.

      10-Q - PRESSURE BIOSCIENCES INC (0000830656) (Filer)

      2/7/25 5:30:43 PM ET
      $PBIO
    • SEC Form 10-Q filed by Pressure BioSciences, Inc.

      10-Q - PRESSURE BIOSCIENCES INC (0000830656) (Filer)

      9/6/24 5:17:19 PM ET
      $PBIO
    • SEC Form NT 10-Q filed by Pressure BioSciences, Inc.

      NT 10-Q - PRESSURE BIOSCIENCES INC (0000830656) (Filer)

      8/19/24 5:20:09 PM ET
      $PBIO